Angiotensin Peptides and Lung Cancer

Abstract

Lung cancer is a leading cause of death in both men and women, with over 1,000,000 new cases diagnosed worldwide annually and a 5-year survival rate of only 14%, a figure that has improved little in the past thirty years. This poor prognosis suggests a need for novel approaches for the treatment and prevention of lung cancer. The renin-angiotensin system is an established, primary regulator of blood pressure, homeostasis, and natriuresis; however, compelling evidence indicates that the angiotensin peptides also play a role in cell proliferation and inflammation. Angiotensin II is a vasoconstrictor, a mitogen, and an angiogenic factor, while angiotensin-(1-7) has vasodilator, anti-proliferative, and anti-angiogenic properties. This review focuses on studies examining the renin-angiotensin system in pulmonary cancers and whether clinical intervention of this pathway may serve as an effective chemotherapeutic and/or chemopreventive modality for lung cancer.

Incidental Receipt of Cardiac Medications and Survival Outcomes Among Patients With Stage III Non–Small-Cell Lung Cancer After Definitive Radiotherapy

“…Physiologically, ACEs degrade angiotensin-I (AT-I) to generate AT-II, which results in hypertension, and to participate in the degradation of bradykinin and the heptapeptide Ang-(1-7). 36 Given as therapy for hypertension, heart failure, and diabetic nephropathy, ACEIs suppress ACE, reduce the production of AT-II, and indirectly block the type 1 and type 2 receptors of AT-II, whereas ARBs selectively block the action of the AT-II type 1 receptor. 37 In vitro and in vivo studies have shown that ACEIs and ARBs suppress tumor growth, tumor-associated angiogenesis, and metastasis, but these effects have not led to improvements in survival in animal models.…”

Mas and Its Related G Protein–Coupled Receptors, Mrgprs

“…In the opposite, Ang-(1-7), the specific agonist of Mas, has been described to have antitumor activities, which could even be therapeutically exploited (Gallagher et al, 2011). The tumorigenic and proproliferative actions of Mas and maybe also the other Mrgprs may only be observed above a certain threshold of overexpression in cells which is normally not reached in vivo.…”

Genetic Association Study of Angiotensin II Receptor Types 1 (A168G) and 2 (T1247G and A5235G) Polymorphisms in Breast Carcinoma among Brazilian Women

“…Several studies support the significant association of AGTR2 signaling with various types of cancer (renal, colorectal, prostate, uterine, breast and pancreatic) [7,21,22,23,24,25]. Initially, the 2 AGTR2 SNPs studied here were only associated with the circulatory system or with metabolism and nutrition disorders [26].…”